Navigation Links
Biomarkers: What can they tell us
Date:12/12/2008

SAN ANTONIO - As cancer researchers move away from the general use of chemotherapy and into more targeted approaches, scientists are working to discover effective ways to measure response and risk. Data presented at the CTRC-AACR San Antonio Breast Cancer Symposium illustrate the cutting edge of biomarker discovery and development.


Reductions in Breast Density Predict Potential Benefit of Tamoxifen
Abstract #61, Jack Cuzick, Ph.D.

A reduction in breast density of at least 10 percent may predict who benefits from the breast cancer preventive effects of tamoxifen. Researchers studied 1,063 women and found that those with reduced breast density after 12 to 18 months of treatment had a 52 percent reduced risk of breast cancer. By contrast, those women who did not have a decrease in breast density had only an eight percent risk reduction.

Full release available/Complete data to be presented at the meeting


Poor Prognosis on Small, HER2 Positive Tumors
Abstract #701, Ana M. Gonzalez-Angula, M.D

Although current guidelines call for no further therapy after surgery on breast tumors one centimeter or smaller, a new study suggests that if these tumors are HER2 positive patients have an increased risk for relapse. In the largest study of its kind to date (n=1,315, including a validation set), researchers found that the five-year recurrence rate was 23 percent among patients with small HER2-positive tumors, compared with eight percent in other tumor types.

Full release available/Complete data to be presented at the meeting


New Genetic Modeling Improves Screening
Abstract #502, Kathie Dalessandri, M.D.

A new genetic model based on 22 single nucleotide polymorphisms may improve the ability to predict risk of developing breast cancer. Researchers found that in a high-risk population from Marin County, California, this model improved diagnostic accuracy by 51 percent compared to classic risk factors alone.

Full release available/Complete data to be presented at the meeting.


New Biomarker Predicts Anthracycline Response
Abstract #45, John Bartlett, Ph.D.

The presence of chromosome 17 polysomy effectively predicted which patients would benefit from adjuvant anthracycline chemotherapy. Researchers analyzed 1,625 samples from NEAT (National Epirubicin Adjuvant Trial) and found that those patients with C17 polysomic tumors had significantly greater benefit from epirubicin than those without, even when taking HER2 status into consideration. Researchers suggest that this may explain the apparent association of anthracycline sensitivity and HER2 status which is located on this chromosome.

Complete data to be presented at the meeting.


Biomarkers May Not Identify Proper Chemotherapy Treatment
Abstract # 705, Angelo Di Leo, M.D., Ph.D.

Chemotherapy treatment selection based on biomarkers may not yet be a valuable practice. Prior studies have suggested that HER2 and topoisomerase II (TOP2A) might predict sensitivity to particular chemotherapy agents. An interim analysis shows that HER2 and TOP2A have a clinically modest and statistically borderline predictive value.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology: